Feasibility and effectiveness evaluation of combined use of adagrasib (Krazati) with other anticancer drugs

Adagrasiib (Krazati) is a selective KRAS G12C inhibitor, mainly used to treat patients with KRAS G12C mutation-related advanced non-small cell lung cancer (NSCLC). With the development of precision therapy, single-targeted drugs may suffer from drug resistance or limited efficacy in some patients, so combination drug strategies have gradually attracted attention. The feasibility and effect evaluation of adagrasib combined with other anti-cancer drugs is an important topic in clinical practice and research, and is of great significance for improving the treatment outcomes of patients with advanced lung cancer.

First of all, it is more feasible to use adagrasib in combination with chemotherapy drugs. Chemotherapy drugs such as paclitaxel or platinum-based drugs directly kill tumor cells by destroying cancer cell DNA or interfering with microtubule function, while adagrasib inhibits signaling pathways by targeting KRAS G12C mutations and blocks tumor growth signals. This mechanistic complementarity allows combination regimens to theoretically enhance antitumor effects. Preclinical studies have shown that the combination of adagrasib and chemotherapy drugs can significantly inhibit tumor proliferation in vitro and in animal models. At the same time, some drug-resistant cells show higher sensitivity to combination therapy, providing a scientific basis for clinical exploration of combination therapy.

Secondly, the combination of adagrasib and immune checkpoint inhibitors (such asPD-1/PD-L1 antibodies) also shows potential efficacy advantages. KRASTumors with mutations are often accompanied by immunosuppression in the tumor microenvironment, and the targeting effect of adagrasib can increase the sensitivity of tumor cells to the immune system. Preliminary clinical data indicate that combining adagrasib with a PD-1 inhibitor can improve the objective response rate (ORR), prolong progression-free survival (PFS) in some patients, and enhance the immune response to a certain extent. The key to combined use is to reasonably evaluate the patient's immune status, tumor burden, and previous treatments to maximize efficacy and control immune-related adverse reactions.

In terms of combined targeted drugs, adagrasib can also be combined with signaling pathway inhibitors such as EGFR and MEK. KRAS G12C Some patients will develop resistance to inhibitor monotherapy, which is usually related to activation of alternative signaling pathways or secondary mutations. Combined inhibition of related pathways can delay the emergence of drug resistance and improve disease control rates. Clinical trials are evaluating the safety and efficacy of adagrasib in combination with MEK inhibitors. Preliminary results show that patients can tolerate the combination regimen, and some patients have experienced more significant tumor shrinkage and disease stabilization.

Safety is an important factor that must be considered when using combined drugs. Although adagrasib itself is well tolerated, adverse reactions may accumulate when combined with chemotherapy or immunotherapy, including hematological abnormalities, gastrointestinal reactions, increased liver function indicators, and immune-related adverse events. In clinical practice, doctors need to reduce risks through dose adjustment, interval adjustment and symptomatic treatment. For example, the dose of chemotherapy drugs can be adjusted appropriately according to the patient's blood routine and liver and kidney function, while immune-related side effects, such as pneumonia, rash or enteritis, should be closely monitored when combined with immunotherapy.

In addition, the development of combination drug strategies should be highly individualized. The patient's age, previous treatment experience, liver and kidney function, tolerance and tumor molecular characteristics all affect the choice of combination regimen. Clinical guidelines recommend that detailed molecular testing and risk assessment should be conducted before implementing combination therapy, and a follow-up plan should be established to ensure that efficacy and safety can be maximized. Taken together, the strategy of combining adagrasib with other anti-cancer drugs shows feasibility and potential advantages in theory and preliminary clinical data, providing more treatment options for patients with KRAS G12C mutations.

In short, the study of adagrasib combined with chemotherapy, immunotherapy or other targeted drugs provides new treatment ideas for patients with advanced KRAS G12C mutationNSCLC. Through complementary mechanisms, delayed drug resistance, and enhanced efficacy, combination therapy is expected to improve patients' objective response rate, prolong progression-free survival, and improve overall survival benefit. However, the combination regimen requires strict monitoring of adverse reactions, development of individualized medication strategies, and implementation under the guidance of a multidisciplinary team to ensure both efficacy and safety. As more clinical research data accumulates in the future, combination therapy is expected to become an important treatment option for patients with KRAS G12C mutations.

Reference materials:https://www.drugs.com/